ENYO Pharma receives Tranche 2 of its Series A investment.
ENYO Pharma has received the 10 M€ Tranche 2 of its Series A investment. The Board of Directors unanimously requested the Investors release this second Tranche of the 22 M€ Series A which closed in January 2016. This release is a response to several successfully achieved milestones, most importantly the Board decision to initiate Phase 1b in chronically infected, HBV patients. The first patients enrolment is planned for Q2 2017.
Read next in 'Latest news'
- Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
- New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH
- New publication : An anti-diabetic drug targets NEET (CISD) proteins through destabilization of their [2Fe-2S] clusters
- Swiss NASH Foundation sponsorship
- ENYO Pharma in the Top 50 of the EIC ScalingUp List